ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO119

Kidney and Patient Survival in Glomerulonephritis: Results from a Mexican Cohort

Session Information

Category: Glomerular

  • 1004 Clinical/Diagnostic Renal Pathology and Lab Medicine

Authors

  • Martínez, Petra, Hospital of Specialties,CMNO,IMSS, Guadaljara, Jalisco, Mexico
  • Mondragon, Liliana, IMSS, Guadalajara, Mexico
  • Gomez-Navarro, Benjamin, IMSS, HECMNO, Zapopan, Jalisco, Mexico
  • Villanueva-Perez, Arisbeth, Patologia y nefropatologia, Guadalajara, Mexico
  • Cueto-Manzano, Alfonso M., None, Zapopan, Jalisco, Mexico
  • Rojas-Campos, Enrique, INSTITUTO MEXICANO DEL SEGURO SOCIAL, GUADALAJARA, Mexico
Background

Background: There is scarce information of glomerulonephritis (GN) survival in our setting. Objective: To evaluate kidney and patient survival in GN.

Methods

Methods: Retrospective cohort. From kidney biopsy records, all cases with GN diagnosis, ≥16 yrs, and any gender, were included; transplant biopsies excluded. Data were obtained from medical charts. At the end of follow-up, patient status was registered as alive, dead or lost, and kidney status as functioning or failure. Statistical Analysis: Kaplan Meier and Log-rank analysis used to evaluate mortality, and Cox Hazard Proportional Model to evaluate mortality risk factors.

Results

Results: 328 biopsies were analyzed; age 33±13 yrs, 67% female, follow-up 35±11 months. Comparison between primary vs secondary GN is shown in Table. Figure A, show the most common clinical presentation. Type of GN: Lupus nephritis 41%, Focal segmental glomerulosclerosis 23%, Membranous nephropathy 12%, other 24%. Figure B and C, shows patient and kidney survival; 32 (10%) developed ESRD, and 15 (5%) died at follow-up. In multivariate analysis, final systolic blood pressure (SBP, RR 1.29, 95%CI: 1.00-1.06, p=0.04), and age (RR 1.03, 95%CI: 0.99-1.07, p=0.06) predicted death, whereas baseline SBP (RR 1.45, 95%CI: 0.83-250, p=0.01) and baseline creatinine (RR 3.09, 95%IC: 1.03-9.26, p=0.02) predicted kidney survival.

Conclusion

Conclusions: Primary GN had lower SBP and higher cholesterol, CrCl and proteinuria at baseline than Secondary GN; however these differences disappeared at the end of follow-up. Patient and kidney survival were similar to other series, and were not different between Primary and Secondary GN.

VariableGN primary GN Secondary 
 BaselineFinalBaselineFinal
SBP (mmHg)122±15120±16125±16*123±15
DBP (mmHg)77±1076±1077±1077±10
Cholesterol (mg/dL)230 (180-270)213 (154-254)£220 (176-265)*214 (152-247)£
CrCl (ml/min/1.73m2)80 (60-107)82 (55-97)69 (42-92)75 (48-94)*
Proteinuria (g/day)3100 (1100-6500)573(228-1400)£1800 (595-3500)*499 (210-1500)£

*p<0.05 vs same evaluation of primary GN; £p<0.05 vs baseline of the same-group.